The end goal of the partnership is to improve referral and diagnostic pathways for patients with possible lung cancers and increase lung cancer detection at an earlier stage – improving the patient journey and ultimately reducing lung cancer mortality rates around the world.
Leon Wang, AstraZeneca EVP International and Country President China, said “Improving long-term outcomes in lung cancer relies heavily on clinicians being able to identify patients in the early stages of the disease – giving them a better chance to provide curative-intent treatment. Qure.ai’s deep learning algorithm-based technology has the potential to provide clinicians with faster, more accurate diagnoses based on chest X-rays, helping secure those early-stage diagnoses and deliver better outcomes for patients. Innovations such as this are critical for boosting the capabilities of healthcare ecosystem, not just in Emerging Markets, but around the world, and this partnership supports our bold ambition of eliminating cancer as a cause of death.”
Ad Statistics
Times Displayed: 50459
Times Visited: 1437 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Prashant Warier, CEO and Co-Founder, Qure.ai, said “We are delighted to partner with AstraZeneca in the early detection of lung cancer using our AI solution for automated interpretation of chest X-rays. The software’s ability to process analogue and digital chest X-rays in a minute can help physicians in incidental diagnoses of lung cancer by pointing out small lung nodules which could have been missed in a cursory review. The solution also detects several other types of abnormalities from chest X-rays that are linked to infection, injuries and chronic diseases, and flags these to the physician, potentially creating other diagnostic pathways.”
About AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
About Qure.ai
Qure.ai is a leading artificial intelligence (AI) solution provider based in Mumbai, India, developing decision support tools for medical imaging professionals, with a particular focus on the diagnosis of pulmonary diseases.
Back to HCB News
